Scholarlink

<p>Cytopenia is a common finding in myelofibrosis. It can be disease-related, a consequence of treatment, or a combination of the aforementioned causes. Cytopenia in myelofibrosis can have an adverse outcome. We aimed to evaluate the incidence of cytopenia at ruxolitinib treatment baseline and its influence on overall and event-free survival. This retrospective study included 57 patients with myelofibrosis treated with ruxolitinib in University Clinical Center of Vojvodina. Patients were devided into two groups according to disease phenotype – cytopenic and proliferative. Cytopenic phenotype at the start of ruxolitinib treatment was present in 61.4% (35) patients. The median overall survival for patients with the cytopenic phenotype was 26&#xa0;months. There was a significant difference between the groups concerning DIPSS score, ruxolitinib starting dose, reaching spleen response after six and twelve months, and outcome. Patients with a cytopenic phenotype at ruxolitinib treatment baseline had a significantly shorter overall survival (HR 2.6963 (95%CI 1.1517—6.3126), p = 0.0223). There were significantly more patients with any cytopenia (p = 0.043), more than one cytopenia (p &lt; 0.0001), anemia (p = 0.00074), and thrombocytopenia (p = 0.00034) after six months of ruxolitinib treatment. Cytopenia after six months of ruxolitinib treatment did not have a significant effect on overall survival and event-free survival (p = 0.122 vs. p = 0.2213). Cytopenias before but not after the start of ruxolitinib treatment have an adverse effect on the outcome and survival of patients with myelofibrosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cytopenic Patients with Myelofibrosis—Inferior Response and Outcome to Treatment with Ruxolitinib

  • 期刊论文

  • 发表日期：

    2026年4月1日

查看全文
  • Ivanka Perčić,
  • Marina Dokić,
  • Ivana Urošević,
  • Dunja Bjelogrlić,
  • Danijela Agić,
  • Jelena Ilić-Sabo,
  • Tanja Lakić

摘要

Cytopenia is a common finding in myelofibrosis. It can be disease-related, a consequence of treatment, or a combination of the aforementioned causes. Cytopenia in myelofibrosis can have an adverse outcome. We aimed to evaluate the incidence of cytopenia at ruxolitinib treatment baseline and its influence on overall and event-free survival. This retrospective study included 57 patients with myelofibrosis treated with ruxolitinib in University Clinical Center of Vojvodina. Patients were devided into two groups according to disease phenotype – cytopenic and proliferative. Cytopenic phenotype at the start of ruxolitinib treatment was present in 61.4% (35) patients. The median overall survival for patients with the cytopenic phenotype was 26 months. There was a significant difference between the groups concerning DIPSS score, ruxolitinib starting dose, reaching spleen response after six and twelve months, and outcome. Patients with a cytopenic phenotype at ruxolitinib treatment baseline had a significantly shorter overall survival (HR 2.6963 (95%CI 1.1517—6.3126), p = 0.0223). There were significantly more patients with any cytopenia (p = 0.043), more than one cytopenia (p < 0.0001), anemia (p = 0.00074), and thrombocytopenia (p = 0.00034) after six months of ruxolitinib treatment. Cytopenia after six months of ruxolitinib treatment did not have a significant effect on overall survival and event-free survival (p = 0.122 vs. p = 0.2213). Cytopenias before but not after the start of ruxolitinib treatment have an adverse effect on the outcome and survival of patients with myelofibrosis.